16 September 2026 editorial review · Item
Remygen (oral GABA) — Diamyd's beta-cell regeneration bet: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. - Claim check: ReGenerate-1 found no C-peptide, HbA1c or CGM benefit, with AST elevation in nine of 35 and two withdrawals. Removed blanket safety confirmation and “benefit in no one” assertions. Pediatric lower-dose explanations remain hypotheses.
- Registry NCT03635437: COMPLETED; updated 2022-11-02; enrollment 35 (ACTUAL); primary completion 2022-09-27 (ACTUAL); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: s41598-025-95751-y; s41467-022-35544-3.